Intra nasal administration of poly-lactic acid microsphere co- encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse

Vaccine

Volumn 16, Issue 7, 1998, Pages 698-707

  Eyles, Jim E ^a   Sharp, Gregory J E ^a   Williamson, E Diane ^b   Spiers, Ian D ^a   Alpar, H Oya ^a  

^a ASTON UNIVERSITY   (United Kingdom)

^b DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Nasal delivery; Pneumonic plague; Protective sub units

Indexed keywords

BACTERIAL VACCINE; UNCLASSIFIED DRUG; YERSINIA VACCINE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; IMMUNOGENICITY; INFECTION PREVENTION; INTRANASAL DRUG ADMINISTRATION; MALE; MICROENCAPSULATION; MOUSE; NONHUMAN; PLAGUE; PRIORITY JOURNAL; VACCINE PRODUCTION; YERSINIA PESTIS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, BACTERIAL; GASTRIC MUCOSA; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LACTIC ACID; MACROMOLECULAR SUBSTANCES; MALE; MICE; MICE, INBRED STRAINS; MICROSPHERES; PLAGUE; POLYMERS; YERSINIA PESTIS;

EID: 0032054624     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00249-1     Document Type: Article

References (47)

1. 1 Perry, R.D. and Fetherston, J.D. Yersinia pestis - etiologic agent of plague. Clinical and Microbiology Review 1997, 10, 35-66.
2. 2 Meyer, K.F. Effectiveness of live or killed plague vaccines in man. Bulletin of the WHO 1970, 4, 653-666.
3. 3 Cleland J.L. In: Vaccine Design. The Subunit and Adjuvant Approach (Eds Powell, M.F. and Newman, M.J.) Plenum Press, New York, 1995, Ch. 7
4. 4 Baker, E.E., Sommer, H., Foster, L.E., Meyer, E. and Meyer, K.F. Studies on immunisation against plague. Journal of Immunology 1952, 68, 131-145.
5. 5 Friedlander, A.M., Welkos, S.L., Worsham, P.L., Andrews, G.P., Heath, D.G., Anderson, G.W., Pitt, M.L.M., Estep, J. and Davis, K. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Clinics in Infectious Disease 1995, 21, (Suppl. 2), S178-181.
6. 6 Nakajima, R. and Brubaker, R.R. Association between virulence of Yersinia pestis and suppression of gamma interferon and tumour necrosis factor alpha. Infection and Immunity 1993, 61, 23-31.
7. 7 Nakajima, R., Motin, V.L. and Brubaker, R.R. Suppression of cytokines in mice by protein A-V fusion peptide and restoration of synthesis by active immunisation. Infection and Immunity 1995, 63, 3021-3029.
8. 8 Williamson, E.D., Eley, S.M., Griffin, K.F., Green, M., Russell, P., Leary, S.E.C., Oyston, P.C.F., Easterbrook, T., Reddin, K.M., Robinson, A. and Titball, R.W. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunity and Medical Microbiology 1995, 12, 223-230.
9. 9 Williamson, E.D., Sharp, G.J.E., Eley, S.M., Vesey, P.M., Pepper, T.C., Titball, R.W. and Alpar, H.O. Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Vaccine 1996, 14, 1613-1619.
10. 10 Anderson, G.W., Leary, S.E.C., Williamson, E.D., Titball, R.W., Welkos, S.L., Worsham, P.L. and Friedlander, A.M. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infection and Immunity 1996, 64, 4580-4585.
11. 11 Williamson, E.D., Eley, S.M., Stagg, A.J., Green, M.G., Russell, P. and Titball R.W. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunised animals against pneumonic plague. Vaccine. 1997, 15, 1079-1084
12. 12 Staats, H.F., Jackson, R.J., Marinaro, M., Takahashi, I., Kiyono, H. and McGhee, J.R. Mucosal immunity to infection with implications for vaccine development. Current Opinion in Immunology 1994, 6, 572-583
13. 13 Mestecky, J., Moldoveanu, Z., Novak, M. and Compans, R.W. Mucosal immunity and strategies for novel microbial vaccines. Acta Paediatrics Japonica 1994, 36, 537-544
14. 14 Walker, R.I. New strategies for using mucosal vaccination to achieve more effective immunisation. Vaccine 1994, 12, 387-400
15. 15 Husband, A.J. Novel vaccination strategies for the control of mucosal infection. Vaccine 1993, 11, 107-112.
16. 16 McGhee, J.R., Mestecky, J.M., Dertzbaugh, M.T., Eldridge, J.H., Hirasawa, M. and Kiyono, H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992, 10, 75-88.
17. 17 Morris, W., Steinhoff, M.C. and Russell, P.K. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 1994, 12, 5-11.
18. 18 Eldridge, J.H., Staas, J.K., Chen, D., Marx, P.A., Tice, T.R. and Gilley, M. New advances in vaccine delivery systems. Seminars in Hematology 1993, 30, 16-25.
19. 19 Tabata, Y. and Ikada, Y. Phagocytosis of polymer microspheres by macrophages. Advances in Polymer Science 1990, 94, 107-141.
20. 20 Vidard, L., Kovacsovics-Bankowski, M., Kraeft, S., Chen, L.B., Benacerraf, B. and Rock, K.L. Analysis of MHC class II presentation of particulate antigens by B lymphocytes. Journal of Immunology 1996, 156, 2809-2818
21. 21 Van Rooijen, N. Antigen processing and presentation in vivo: the microenvironment as a crucial factor. Immunology Today 1990, 11, 436-439.
22. 22 O'Hagan, D.T., Palin, K., Davis, S.S., Artursson, P. and Sjohölm, I. Microparticles as potentially orally active immunological adjuvants. Vaccine 1989, 7, 421-424.
23. 23 Jenkins, P.G., Coombes, A.G.A., Yeh, M.K., Thomas, N.W. and Davis, S. Aspects of the design and delivery of microparticles for vaccine applications. Journal of Drug Targeting 1995, 3, 79-81.
24. 24 Lyke, N. and Holmgren, J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 1986, 59, 301-308.
25. 25 Wu, H.-Y. and Russel, M.W. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with cholera toxin B subunit. Infection and Immunity 1993, 61, 314-322.
26. 26 Almeida, A.J. and Alpar, H.O. Nasal delivery of vaccines. Journal of Drug Targeting 1996, 3, 455-467.
27. 27 Mielcarek, N., Cornette, J., Schacht, A., Pierce, R.J., Locht, C., Capron, A. and Riveau, G. Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune responses against a heterologous antigen. Infection and Immunity 1997, 65, 544-550.
28. 28 Yan, C., Rill, W.L., Malli, R., Hewetson, J., Naseem, H., Tammariello, R. and Kende, M. Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres. Vaccine 1996, 14, 1031-1038.
29. 29 Almeida, A.J., Alpar, H.O. and Brown, M.R.W. Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(L-lactic acid) microspheres in rats, rabbits and guinea-pigs. Journal of Pharmacy and Pharmacology 1993, 45, 198-203.
30. 30 Cremaschi, D., Rossetti, C., Draghetti, M.T., Manzoni, C. and Aliverti, V. Active transport of polypeptides in rabbit nasal mucosa: possible role in the sampling of potential antigens. Pflügers Archiv - European Journal of Physiology 1991, 419, 425-432.
31. 31 Zhou, X.H. and Li Wan Po, A. Peptide and protein drugs: II. non-parenteral routes of delivery. International Journal of Pharmaceutics 1991, 75, 117-130.
32. 32 Brandenberg, P. Immune functions of human nasal mucosa and tonsils in health. In: Immunology of the Lung and Upper Respiratory Tract (Ed. Bienenstock J.) McGraw-Hill, New York, 1984, pp. 28-95
33. 33 Spit, B.J., Hendriksen, E.G.J., Bruijntjes, J.P. and Kuper, C.F. Nasal lymphoid tissue in the rat. Cell and Tissue Research 1989, 255, 193-198.
34. 34 Leary, S.E.C., Williamson, E.D., Griffin, K.F., Russell, P., Eley, S.M. and Titball, R W. Active immunisation with recombinant V antigen from Yersinia pestis protects mice against plague. Infection and Immunity 1995, 63, 2854-2858.
35. 35 Beck, L.R., Cowsar, D.R., Lewis, D.H., Cosgrove, J.R., Lowry, S.L. and Epperly, T.A. A new long-acting microcapsule system for administration of progesterone. Fertility and Sterility 1979, 31, 545-551.
36. 36 Xing, D.K.L., McLellan, K., Corbel, M.J. and Sesardic, D. Estimation of tetanus toxoid extracted from biodegradable microspheres. Biologicals 1996, 24, 57-65.
37. 37 Smith, P.K., Krohn, R.I., Hermanson, G.T., Mallia, A.K., Gartner, F.H., Provenzano, M.D., Fujimoto, E.T., Goeke, N.M., Olson, B.J. and Klenk, D.C. Measurement of proteins using bicinchoninic acid. Analytical Biochemistry 1985, 150, 76-85.
38. 38 Elson, C.O., Ealding, L.O. and Lefkowitz, J. A lavage technique allowing repeated measurement of IgA antibody in mouse intestinal secretions. Journal of Immunological Methods 1984, 67, 101-108.
39. 39 May, K.R. The Collison nebuliser: description, performance and application. Aerodynamic Science 1973, 4, 235-243.
40. 40 Henderson, D.W. An apparatus for the study of airborne infections. Journal of Hygiene 1952, 50, 53-68.
41. 41 Campbell R.C. Statistics for Biologists. Cambridge University Press Ltd, Cambridge, 1988
42. 42 Gizurarson, S., Tamura, S., Aizawa, C. and Kurata, T. Stimulation of the transepithetial flux of influenza vaccine by cholera toxin B subunit. Vaccine 1992, 10, 101-106.
43. 1-receptor binding enhances later events in differentiation. Journal of Immunology 1993, 150, 4810-4821.
44. 44 Nashar, T.O. and Hirst, T.R. Immunoregulatory role of H-2 and intra-H-2 alleles on antibody responses to recombinant preparations of B-subunits of E. coli heat labile enterotoxin (rEtxB)and cholera toxin (rCtxB). Vaccine 1995, 13, 803-810.
45. 45 Hörnquist, E., Lycke, N., Czerkinsky, C. and Holmgren In: Novel Delivery Systems for Oral Vaccines (Ed. O'Hagan, D.T ) CRC Press, Boca Raton, 1994, pp. 157-174
46. 46 O'Hagan, D.T. In: Novel Delivery Systems for Oral Vaccines (Ed. O'Hagan, D.T.) CRC Press, Boca Raton, 1994, pp. 1-26
47. 47 Alpar, H.O., Almedia, A.J. and Brown, M.R.W. Microspheres absorption by the nasal mucosa of the rat. Journal of Drug Targeting, 1994, 2, 147-149